The per-injection reaction risk is likely similar across medications
Glucagon Often thought of purely as a blood sugarraising hormone, glucagon also has beneficial effects when balanced carefully with GLP-1 and GIP
Recent multi-omics analyses by Cappellani et al., for instance, have provided strong genetic and proteomic evidence linking DR pathogenesis directly to the activation of specific immune pathways, including the complement system and adaptive T-cell responses [53, 58, 59]
In the future, with the in-depth exploration of the mechanism of GLP-1R action and the development of multi-target agonists (e.g., GLP-1R/GIPR dual agonists), GLP-1R-related therapeutics are expected to make breakthroughs in a wider range of disease areas (e.g., nonalcoholic steatohepatitis, AD, etc.), providing a more precise and highly effective strategy for the treatment of metabolic diseases and related complications